Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy

Conventional chemotherapy drugs administered at a maximum tolerated dose (MTD) remains the backbone for treating most cancers. Low-dose metronomic (LDM) chemotherapy, which utilizes lower, less toxic, doses given on a close regular basis over prolonged periods, is an alternative and better tolerated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2016-10, Vol.76 (20), p.5983-5993
Hauptverfasser:	Shaked, Yuval, Pham, Elizabeth, Hariharan, Santosh, Magidey, Ksenia, Beyar-Katz, Ofrat, Xu, Ping, Man, Shan, Wu, Florence T H, Miller, Valeria, Andrews, David, Kerbel, Robert S
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antimetabolites, Antineoplastic - therapeutic use Bone Marrow Cells - pathology Capecitabine - therapeutic use Cell Line, Tumor Female Humans Maximum Tolerated Dose Mice Neoplasms, Experimental - drug therapy Neoplasms, Experimental - immunology Neoplasms, Experimental - mortality Neoplasms, Experimental - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!